8-K: Organon's HADLIMA Achieves Full Interchangeability with Humira, Boosting Biosimilar Market Access and Patient Savings

Organon & Co. announced that the U.S. FDA has granted full interchangeability designation to its biosimilar HADLIMA (adalimumab-bwwd) with all presentations of Humira (adalimumab), enabling direct pharmacy substitution and potentially increasing patient access and healthcare savings.

Summary

• The U.S. Food and Drug Administration (FDA) has designated Organon and Samsung Bioepis' HADLIMA (adalimumab-bwwd) highand low-concentration autoinjectors and high-concentration prefilled syringe as interchangeable biosimilars to Humira (adalimumab).
• This new designation, combined with a previous one in June 2024 for the low-concentration prefilled syringe and single-dose vial, means HADLIMA is now interchangeable with all presentations of the reference product, Humira.
• Interchangeability allows pharmacists to substitute HADLIMA for Humira without consulting the prescriber, subject to state pharmacy laws, which is expected to improve patient access to biologic therapies.
• Increased uptake of biosimilars like HADLIMA may lead to potential savings for the U.S. healthcare system.
• An analysis of patient claims from July 2023 to August 2024 showed that patients paid an average of $48 per month out-of-pocket for HADLIMA, compared to $215 for Humira.
• The interchangeability designation was supported by clinical data from a study in patients with moderate to severe plaque psoriasis, demonstrating comparability in pharmacokinetics, efficacy, safety, and immunogenicity between switching to SB5 (HADLIMA) and continuous Humira treatment.
• HADLIMA is indicated for various conditions including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis.

Sentiment

Score: 9

Explanation: The announcement is overwhelmingly positive, granting full interchangeability to a key biosimilar, which is a significant competitive advantage and is expected to drive market adoption and cost savings. This is a major regulatory and commercial milestone.

Positives

• Full interchangeability designation for HADLIMA with all Humira presentations significantly enhances market access and ease of substitution.
• The ability for pharmacists to substitute HADLIMA for Humira without prescriber consultation is expected to increase patient access to biologic therapies.
• HADLIMA offers substantial cost savings for patients, with average out-of-pocket costs of $48 per month compared to $215 for Humira.
• The designation is based on robust clinical data demonstrating comparability in pharmacokinetics, efficacy, safety, and immunogenicity.
• This approval reinforces Organon's commitment to making biosimilars more accessible and contributing to healthcare system savings.

Risks

• Patients treated with adalimumab products, including HADLIMA, are at increased risk for developing serious infections that may lead to hospitalization or death, including active tuberculosis, invasive fungal infections, and other opportunistic pathogens.
• Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including adalimumab products, with postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL) noted.
• Hypersensitivity reactions, including anaphylaxis and angioneurotic edema, have been reported following adalimumab administration.
• Use of TNF blockers, including HADLIMA, may increase the risk of reactivation of hepatitis B virus (HBV) in chronic carriers, with some fatal cases reported.
• Rare cases of new onset or exacerbation of central nervous system and peripheral demyelinating diseases, such as multiple sclerosis, optic neuritis, and Guillain-Barré syndrome, have been associated with TNF blockers.
• Rare reports of pancytopenia, including aplastic anemia, and medically significant cytopenia have been reported with TNF blockers.
• Worsening and new onset congestive heart failure (CHF) have been reported with TNF blockers.
• Treatment with adalimumab products may result in the formation of autoantibodies and, rarely, in development of a lupus-like syndrome.
• Patients on HADLIMA should not receive live vaccines, and pediatric patients should be up-to-date on immunizations before therapy.
• General business risks include expanded brand and class competition, trade protection measures, changes in governmental funding, economic factors (inflation, interest rates, recession), market volatility, difficulties with third-party performance, increased supply and manufacturing costs, regulatory disruptions, pricing pressures, and product safety concerns.

Future Outlook

The company anticipates that the full interchangeability designation for HADLIMA will lead to increased uptake of the biosimilar, potentially resulting in improved patient access to biologic therapies and significant savings for the U.S. healthcare system. Organon continues to invest in innovative solutions and research to drive future growth opportunities in biosimilars and seeks collaborations to commercialize products leveraging its global scale.

Management Comments

• Jon Martin, US Commercial Lead, Biosimilars and Established Brands at Organon, stated: "With this approval, pharmacies can substitute HADLIMA for the reference product Humira without consulting prescribers (subject to state law), which may facilitate increased access for patients to receive the medications they need."
• Byoung In Jung, Vice President and Regulatory Affairs Team Leader at Samsung Bioepis, commented: "This designation is meaningful as it signifies our continued commitment to making biosimilars more accessible. Both biosimilars and interchangeable biosimilars are highly similar and have no clinically meaningful differences in safety, purity, and potency compared to the reference product."

Industry Context

This FDA interchangeability designation for HADLIMA is a significant development in the biosimilar market, particularly for adalimumab biosimilars, which compete with AbbVie's blockbuster drug Humira. Full interchangeability removes a key barrier to biosimilar adoption by allowing direct pharmacy-level substitution, potentially accelerating market penetration and increasing competition. This aligns with broader industry trends towards increasing biosimilar utilization to drive down healthcare costs and expand patient access to complex biologic therapies.

Comparison to Industry Standards

• HADLIMA (adalimumab-bwwd) is now fully interchangeable with all presentations of Humira (adalimumab), the reference product. This means it meets the highest standard for biosimilarity, allowing for direct substitution at the pharmacy level, a critical factor for market penetration.
• The average out-of-pocket cost for HADLIMA ($48/month) is significantly lower than that for Humira ($215/month), demonstrating a clear cost-benefit for patients compared to the originator product.
• The clinical data supporting interchangeability, based on a study comparing SB5 (HADLIMA) to EU-sourced Humira in patients with moderate to severe plaque psoriasis, aligns with the rigorous standards set by the FDA for interchangeable biosimilar approvals.

Stakeholder Impact

• **Shareholders**: Positive impact due to enhanced market position and potential for increased sales and revenue from HADLIMA, a key biosimilar product.
• **Patients**: Highly positive impact through improved access to a lower-cost biologic therapy (HADLIMA) for various chronic inflammatory conditions, potentially reducing out-of-pocket expenses.
• **Healthcare Providers (Prescribers)**: May experience simplified prescribing processes as pharmacists can directly substitute HADLIMA for Humira, reducing administrative burden.
• **Pharmacists**: Gain increased autonomy in dispensing, allowing for direct substitution of HADLIMA for Humira, subject to state laws.
• **Healthcare System**: Potential for significant cost savings due to increased adoption of a more affordable biosimilar, contributing to overall healthcare efficiency.

Next Steps

• Organon and Samsung Bioepis will continue to commercialize HADLIMA in the U.S. market, leveraging the new interchangeability designation to increase patient access and market share.
• Monitoring of state pharmacy laws will be crucial as the ability to substitute HADLIMA for Humira without prescriber consultation is subject to these laws.

Key Dates

Recommendation

Keywords

Biosimilar, Adalimumab, HADLIMA, Humira, FDA, Interchangeability, Organon, Samsung Bioepis, Rheumatoid Arthritis, Plaque Psoriasis, Crohn's Disease, Ulcerative Colitis, Healthcare Savings, Biologic Therapy, Pharmaceuticals